Overview

An Open-label Study of XEN1101 in Epilepsy

Status:
Not yet recruiting

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the long term safety, tolerability, PK, and efficacy of XEN1101 25 mg QD taken orally in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 3 years.

Phase:

Phase 3

Details

Lead Sponsor:

Xenon Pharmaceuticals Inc.

Collaborator:

Worldwide Clinical Trials